CA-QAD-INC
14.5.2024 09:01:37 CEST | Business Wire | Press release
QAD Inc., a leading provider of next-generation manufacturing and supply chain solutions in the cloud, has opened registration for its new EMEA customer conference, QAD Transform Europe, a complimentary two-day event happening 24-25 September in Brussels, Belgium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514413631/en/
Customers, sponsors and other members of the QAD community will join manufacturing and supply chain leaders from across Europe for two days of networking, education and technology innovation. Attendees will hear from industry experts and peers about the state of manufacturing and supply chains, what the future may bring and how to stay adaptive.
“QAD Transform Europe is our fresh take on regional events designed for and tailored to the customer,” said QAD Chief Product and Marketing Officer Carter Lloyds. “We recognize that manufacturing and supply chain leaders continue to face uncertainty and change in their business. The only way to survive and thrive is to transform. We look forward to sharing our roadmap for transformation at the event.”
The agenda for QAD Transform Europe will address the fundamental reasons businesses need to transform to survive, and help map the journey to get there. QAD leaders will outline the company’s plans for how to navigate today and tomorrow and QAD customers will share their success stories.
Agenda Highlights:
- Introducing the Industrial Transformation Platform — QAD’s roadmap to help companies transform into an Adaptive Enterprise by QAD CEO Anton Chilton
- Panel discussion with industry leaders on the transformation imperative
- Effective change management across your organization
- Uncovering root causes — not symptoms — of supply chain disruption
- Keynote address on QAD’s technology strategy and the benefits of the Cloud with QAD CTO Tony Winter
- Keynote address on Artificial Intelligence with Jeroen Baert, Computer Scientist, Comedian, Geek
- Leveraging pragmatic AI in supply chains
- Aligning ESG and sustainability with commercial objectives
- QAD new flagship ERP release — ERP O³
- Product updates on QAD Redzone Connected Workforce, QAD GTTE, QAD SRM, QAD DSCP and QAD Process Intelligence
- The new QAD roadmap for the food and beverage industry
- Breakout sessions and QAD Sponsor Expo
On Day 1, QAD executives and guest speakers will share an update on QAD today and the Industrial Transformation Platform, a panel discussion with industry experts on the need for transformation, the QAD roadmap and customer success stories. A networking reception and dinner with fellow manufacturing and supply chain leaders will follow.
On Day 2, guest keynotes will present on Effective Change Management, followed by a presentation on the state of Artificial Intelligence. More great breakout sessions and a networking lunch with QAD will follow as well as a Sponsor Expo to see QAD solutions in action.
The full agenda can be accessed here. For the latest updates on QAD Transform Europe, follow us on social media and engage using #QADTransform.
Event Details
What: QAD Transform Europe Customer Conference
When: 24-25 September, 2024
Where: Cardo Brussels Hotel | Brussels, Belgium
Registration: To register to attend QAD Transform Europe, click here.
About QAD – Enabling Adaptive Enterprises
QAD Inc. is a leading provider of next-generation manufacturing and supply chain solutions in the cloud. To succeed in a turbulent world, facing disruptions in supply and fluctuations in demand, manufacturers and supply chains must rapidly respond to change and seamlessly optimize agility, efficiency, and resilience for effective customer service. QAD delivers Adaptive Applications to enable these Adaptive Enterprises.
Founded in Santa Barbara, California, QAD has customers in 84 countries around the world. Thousands of companies have deployed QAD enterprise solutions including enterprise resource planning (ERP), digital commerce (DC), supplier relationship management (SRM), digital supply chain planning (DSCP), global trade and transportation execution (GTTE), enterprise quality management system (EQMS), connected workforce and process intelligence. To learn more, visit www.qad.com or call +1 805-566-6100. Find us on LinkedIn, X, Facebook and Instagram.
“QAD” is a registered trademark of QAD. All other products or company names herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514413631/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom